1. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007 3;245(3):366-378. PMID:
17435543.
2. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007 2;14(2):730-738. PMID:
17103065.
3. Arita K, South AP, Hans-Filho G, Sakuma TH, Lai-Cheong J, Clements S, et al. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008 1;82(1):73-80. PMID:
18179886.
4. Isozaki O, Tsushima T, Miyakawa M, Emoto N, Demura H, Arai M, et al. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture. Thyroid. 1997 2;7(1):71-77. PMID:
9086575.
5. Klausen P, Pedersen L, Jurlander J, Baumann H. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 2000 7;19(32):3675-3683. PMID:
10951574.
6. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003 8;374(Pt 1):1-20. PMID:
12773095.
7. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol. 2003 6;149:39-52. PMID:
12811586.
8. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, et al. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999 6;18(25):3742-3753. PMID:
10391682.
9. Grant SL, Begley CG. The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today. 1999 9;5(9):406-412. PMID:
10462753.
10. Lacreusette A, Nguyen JM, Pandolfino MC, Khammari A, Dreno B, Jacques Y, et al. Loss of oncostatin M receptor [beta] in metastatic melanoma cells. Oncogene. 2006 8;26(6):881-892. PMID:
16909117.
11. Mori S, Murakami-Mori K, Bonavida B. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Res. 1999;Mar-Apr;19(2A):1011-1015. PMID:
10368647.
12. Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science. 1992 3;255(5050):1432-1434. PMID:
1542793.
13. Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med. 1994 4;179(4):1337-1342. PMID:
8145045.
14. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med. 1994 4;179(4):1343-1347. PMID:
8145046.
15. Takamatsu J, Hosoya T, Tsuji M, Yamada M, Murakami Y, Sakane S, et al. Peroxidase and coupling activities of thyroid peroxidase in benign and malignant thyroid tumor tissues. Thyroid. 1992 1;2(3):193-196. PMID:
1422230.
16. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science. 2002 6;296(5576):2225-2229. PMID:
12029063.
17. Brown TJ, Lioubin MN, Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes: synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol. 1987 11;139(9):2977-2983. PMID:
3117884.
18. Liu J, Spence MJ, Wallace PM, Forcier K, Hellstrom I, Vestal RE. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Differ. 1997 6;8(6):667-676. PMID:
9186000.
19. Deng G, Kakar S, Okudiara K, Choi E, Sleisenger MH, Kim YS. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs. Clin Cancer Res. 2009 3;15(5):1519-1526. PMID:
19223499.
20. Halfter H, Lotfi R, Westermann R, Young P, Ringelstein EB, Stogbauer FT. Inhibition of growth and induction of differentiation of glioma cell lines by oncostatin M (OSM). Growth Factors. 1998 3;15(2):135-147. PMID:
9505169.
21. Kurebayashi J, Otsuki T, Tanaka K, Yamamoto Y, Moriya T, Sonoo H. Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2. Thyroid. 2003 3;13(3):249-258. PMID:
12729473.
22. Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer. Cytokine. 2010 6;50(3):229-233. PMID:
20381375.
23. Lee J, Rhee Y, Lee S, Ahn CW, Cha BS, Kim KR, et al. Frequent, aggressive behaviors of thyroid microcarcinomas in Korean patients. Endocr J. 2006 10;53(5):627-632. PMID:
16896263.
24. Sugino K, Ito K Jr, Ozaki O, Mimura T, Iwasaki H, Ito K. Papillary microcarcinoma of the thyroid. J Endocrinol Invest. 1998;Jul-Aug;21(7):445-448. PMID:
9766259.
25. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998 8;83(3):553-559. PMID:
9690549.
26. Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol. 2008 3;97(3):221-225. PMID:
18050283.
27. Antonaci A, Anello A, Aucello A, Consorti F, Della Rocca C, Giovannone G, et al. Microcarcinoma and incidental carcinoma of the thyroid in a clinical series: clinical behaviour and surgical management. Clin Ter. 2006;May-Jun;157(3):225-229. PMID:
16900848.
28. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002 8;26(8):879-885. PMID:
12016468.